ARCA Filing For Bucindolol Could Bring First Genetically Targeted CV Therapy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA has accepted an NDA for Gencaro (bucindolol), which could be the first cardiovascular drug approved with an accompanying pharmacogenomic test, ARCA Biopharma said Sept. 23